Protein S-palmitoylation is a post-translational lipid modification that regulates the stability and cellular distribution of numerous cancer-related proteins. A family of 23 palmitoyl transferases, called zinc finger Asp-His-His-Cys-type (ZDHHC), mediates this lipid modification. However, the potential role of palmitoyl transferases in tumor progression and immunotherapy in pancreatic adenocarcinoma (PAAD) remains unexplored.
Multivalent vaccines that could improve SARS-CoV-2 immunity while also preventing infections by other viruses, such as influenza and respiratory syncytial viruses, constitute an urgent public health need. Currently approved vaccines against SARS-CoV-2 are based solely on the spike protein, which provides limited immunity against variations in spike.
Around 73,000 women are diagnosed with triple-negative breast cancer (TNBC) every year in the U.S. and EU. TNBC grows and spreads faster than other types of breast cancer; moreover, it has less treatment options, and usually, a worse prognosis.
Suzhou Genassist Therapeutic Co. Ltd. has announced its pre-IND application of its first base-editing product, GEN-6050, and acceptance by the FDA. GEN-6050 is an in vivo base-editing drug that targets exon 50 skipping in the Duchenne muscular dystrophy (DMD) gene.
Esophageal remodeling occurs during the development of eosinophilic esophagitis (EoE); syndecan-1, also known as CD138, is a cell surface marker involved in extracellular remodeling and it has been shown to be differentially expressed in tissue from patients with EoE compared to healthy esophageal tissue. University of North Carolina at Chapel Hill researchers conducted studies to validate serum CD138 levels as a noninvasive tool for the diagnosis of EoE.
A method for parallel sequencing of single-cell extrachromosomal circular DNA (ecDNA) and full-length mRNA transcriptomes has enabled new insights into the roles of ecDNA in cancer progression, researchers from Charité hospital and the Max Delbrück Center for Molecular Medicine reported in Nature Genetics on May 8, 2023. Circular DNAs are present in at least a third of cancer cells, and their presence correlates with poor prognosis in many cases. They can carry driver genes that have separated themselves from their chromosome of origin, and some research suggests that they serve as “reserve copies” of driver genes. Boundless Bio Inc. is in phase I trials targeting ecDNAs.
Biosplice Therapeutics Inc. has described 1H-pyrrolo[2,3-b]pyridines acting as dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) inhibitors reported to be useful for the treatment of cancer, diabetes and neurological disorders.
Gossamer Bio Inc. has divulged trisubstituted pyridines acting as non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of asthma, atopic dermatitis, contact dermatitis, inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis and allergic rhinitis, among others.
RSS
